Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F12%3A10129300" target="_blank" >RIV/00179906:_____/12:10129300 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/12:10129300 RIV/00023736:_____/12:00009607 RIV/00216224:14110/12:00074593

Výsledek na webu

<a href="http://dx.doi.org/10.1111/j.1439-0507.2012.02186.x" target="_blank" >http://dx.doi.org/10.1111/j.1439-0507.2012.02186.x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/j.1439-0507.2012.02186.x" target="_blank" >10.1111/j.1439-0507.2012.02186.x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience

Popis výsledku v původním jazyce

The objective of this retrospective study was to evaluate results from voriconazole therapeutic drug monitoring (TDM) in haematological patients in routine clinical practice. Between 2005 and 2010, 1228 blood samples were obtained from 264 haematologicalpatients (median 3 samples/patient; range 127) receiving voriconazole for targeted/preemptive treatment of invasive aspergillosis (IA) (46.3% of samples), empirical therapy (12.9%) or prophylaxis (40.8%). A high-pressure liquid chromatography assay wasused to analyse voriconazole concentrations. Clinical and laboratory data were analysed retrospectively. The median of the detected voriconazole plasma concentration was 1.00 mu g ml-1 (range <0.2013.47 mu g ml-1). Significant inter- and intra-patients variability of measured concentrations (81.9% and 50.5%) were identified. With the exception of omeprazole administration, there was no relevant relationship between measured voriconazole concentrations and drug dose, route administration,

Název v anglickém jazyce

Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience

Popis výsledku anglicky

The objective of this retrospective study was to evaluate results from voriconazole therapeutic drug monitoring (TDM) in haematological patients in routine clinical practice. Between 2005 and 2010, 1228 blood samples were obtained from 264 haematologicalpatients (median 3 samples/patient; range 127) receiving voriconazole for targeted/preemptive treatment of invasive aspergillosis (IA) (46.3% of samples), empirical therapy (12.9%) or prophylaxis (40.8%). A high-pressure liquid chromatography assay wasused to analyse voriconazole concentrations. Clinical and laboratory data were analysed retrospectively. The median of the detected voriconazole plasma concentration was 1.00 mu g ml-1 (range <0.2013.47 mu g ml-1). Significant inter- and intra-patients variability of measured concentrations (81.9% and 50.5%) were identified. With the exception of omeprazole administration, there was no relevant relationship between measured voriconazole concentrations and drug dose, route administration,

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Mycoses

ISSN

0933-7407

e-ISSN

—

Svazek periodika

55

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

483-492

Kód UT WoS článku

000309888700003

EID výsledku v databázi Scopus

—